Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07449481 | A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors | withdrawn | Phase 2 | 0 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 |
| clinicaltrials |
| NCT05660421 | Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors | withdrawn | Phase 2 | 0 | Douglas JohnsonOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT05982522 | IN10018 Combination Therapy in Previously-treated Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06331598 | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)(IMperator) | withdrawn | Phase 2 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 6, 2024 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05284214 | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors(SALIENT) | withdrawn | Phase 2 | 0 | Partner Therapeutics, Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations(NEWEL) | withdrawn | Phase 1 / Phase 2 | 0 | Helsinn Healthcare SAINDUSTRY | 3 | Feb 23, 2023 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT03427320 | Imaging of Advanced Tumours Using [131]I-IAZA | withdrawn | Phase 1 / Phase 2 | 0 | University of AlbertaOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05165849 | A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Zhejiang Genfleet Therapeutics Co., Ltd.INDUSTRY | 0 | May 20, 2022 | clinicaltrials |
| NCT04809012 | Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Mar 25, 2022 | clinicaltrials |
| NCT03868423 | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | withdrawn | Phase 2 | 0 | Sameek RoychowdhuryOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT04655183 | Study of M4344 in Combination With Niraparib | withdrawn | Phase 1 / Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 30, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04455958 | Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 26, 2021 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | withdrawn | Phase 2 | 0 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 12, 2020 | clinicaltrials |
| NCT02747537 | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT03147976 | QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors | withdrawn | Phase 2 | 0 | NantPharma, LLCINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03166176 | Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy(TSC1/2_SC) | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT03166904 | Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy(RICTOR_SC) | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT03266159 | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 8, 2017 | clinicaltrials |
| NCT02766842 | Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02656849 | BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Sep 17, 2015 | clinicaltrials |
| NCT02120118 | Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors | withdrawn | Phase 2 | 0 | Shin Kong Wu Ho-Su Memorial HospitalOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT01940601 | Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors | withdrawn | Phase 2 | 0 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | Jan 14, 2015 | clinicaltrials |
| NCT01644097 | Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | Feb 14, 2014 | clinicaltrials |
| NCT01101412 | Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 15, 2013 | clinicaltrials |
| NCT00159016 | Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study. | withdrawn | Phase 2 | 100 | Hadassah Medical OrganizationOTHER | 1 | Apr 28, 2011 | clinicaltrials |
| NCT00148993 | Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors | withdrawn | Phase 1 / Phase 2 | 100 | Hadassah Medical OrganizationOTHER | 1 | Apr 8, 2011 | clinicaltrials |
| NCT00149019 | Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. | withdrawn | Phase 2 | 12 | Hadassah Medical OrganizationOTHER | 1 | Apr 8, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2026source: clinicaltrials